PROM1 and neoplasm: Most interestingly, the injection of Ad-TYML at low dose (3 × 109 vp) resulted in a remarkably greater anti-tumor effect than AdML-5WT at high dose (1 × 1010 vp), indicating significantly stronger anti-tumor effect of the CD133-targeted OAd.